Whitehawk Therapeutics (WHWK) Short term Debt (2020 - 2021)
Whitehawk Therapeutics (WHWK) reported Short term Debt of $258000.0 for Q4 2021, down 98.2% year-over-year from $14.3 million in Q4 2020, and up 1072.73% on a QoQ basis from $22000.0 in Q3 2021.
Whitehawk Therapeutics (WHWK) has 2 years of Short term Debt data on file, last reported at $258000.0 in Q4 2021.
- Quarterly Short term Debt fell 98.2% year-over-year to $258000.0 in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $258000.0 (down 98.2% YoY) and the FY2021 annual result came in at $258000.0, down 98.2% from the prior year.
- Short term Debt advanced to $258000.0 in Q4 2021 per WHWK's latest filing, from $22000.0 in the prior quarter.
- Across five years, Short term Debt topped out at $14.3 million in Q4 2020 and bottomed at $22000.0 in Q3 2021.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Whitehawk Therapeutics | 312.26 Mn | 189.22 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 258,000.00 |
| Sep 30, 2021 | 22,000.00 |
| Dec 31, 2020 | 14.31 Mn |